[Treatment of adult acute lymphoblastic leukemia]

[Treatment of adult acute lymphoblastic leukemia] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

[Treatment of adult acute lymphoblastic leukemia] Abstract Text:

In patients with adult ALL, substantial progress has been made in the past 20 years. At present a cure rate of 30-40% can be achieved and varies in defined subgroups between 10-51%. ALL does not represent an uniform disease but is formed by biologic subentities, which differ in their natural history, clinical presentation and prognosis. A comprehensive diagnostic examination, including morphology, cytochemistry, immunology, cytogenetic and molecular genetic analysis is a precondition for prognostic assessment and therapeutic stratification. The basic principle of ALL treatment is a combination chemotherapy with sequential administration of induction, consolidation and maintenance therapy. Bone marrow transplantation has become an important part of the treatment strategy and is performed in patients with high risk. In the subgroup of T-ALL a significant progress has been made in the last years with survival rates of 40-50%. In B-ALL the results have been greatly improved to 48-51% by introduction of a specific treatment strategy. However, the results (about 30%) stagnate for the total group of B-lineage-ALL (common ALL, pre-B-ALL, pro-B-ALL). Patients with B-lineage-ALL can be subdivided in a high and low risk group according to the presence of risk factors (age, white blood cell count, time to achieve a complete remission, pro-B-ALL and the translocations t[4;11], t[9;22]). The outcome of the subgroup of adult pro-B-ALL has been substantially improved (50%). An increase of treatment results (20%) appears in outlines for patients above 50 years. The Ph/bcr-abl positive ALL has in spite of improved complete remission rates (60-70%) consistently unfavourable survival rates (10%).

[Treatment of adult acute lymphoblastic leukemia] Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

[Treatment of adult acute lymphoblastic leukemia] Journal Published:

PUBLICATION TYPE: Review

Journal: Praxis

VOLUME: 88

Page Numbers: 407-20

Journal Abbreviation:

ISSN: 1661-8157

DAY: 4

MONTH: Mar

YEAR: 1999

[Treatment of adult acute lymphoblastic leukemia] Information

Number of References: 73

LANGUAGE: ger

NlmUniqueID: 101468093

[Treatment of adult acute lymphoblastic leukemia] Keywords Mesh Terms:

KEYWORDS: Precursor Cell Lymphoblastic Leukemia-Ly

MESH TERMS: therapy

Chemical & Substance for Abstract: [Treatment of adult acute lymphoblastic leukemia] Information

Substance Name:

Registry Number:

Grant and Affiliation Information for [Treatment of adult acute lymphoblastic leukemia]

AFFILIATION: Medizinische Klinik III (Hämatologie/Onkologie/Rheumatologie/Infektiologie), Universitätsklinikum, Frankfurt/M.

Country: SWITZERLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Praxis (Bern 1994)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Treatment of adult acute lymphoblastic leukemia Related Publications

• Current status of ALL/AUL therapy in adults.
• Cytobiology and clinical findings of myelodysplastic syndromes.
• Hemopoietic growth factors in the treatment of acute leukemias and myelodysplastic syndromes.
• High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma : comparison of results in human immunodeficiency virus-infected and noninfected patients.
• Recombinant human interleukin-3 in patients with hematopoietic failure.
• [Antibiotic therapy in leukopenia]
• [Growth factors in oncology: effectiveness and prospects]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Not Available.]
• [Treatment of adult acute lymphoblastic leukemia]